Gene hypermethylation in multiple myeloma: Lessons from a cancer pathway approach

Clinical Lymphoma and Myeloma

Volumn 8, Issue 6, 2008, Pages 331-339

  Chim, Chor ^a   Kwong, Yok ^a   Liang, Raymond ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

5 Azacytidine; Interleukin 6; Methylation specific polymerase chain reaction; catenin

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; AZACITIDINE; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DEATH ASSOCIATED PROTEIN KINASE; INTERLEUKIN 6; JANUS KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT PROTEIN; WNT PROTEIN; DNA;

ARTICLE; CANCER SURVIVAL; CELL CYCLE REGULATION; DEMETHYLATION; DISEASE ASSOCIATION; DOWN REGULATION; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; METHYLATION; MICROARRAY ANALYSIS; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; ONCOGENE; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE; UPREGULATION; BIOLOGICAL MODEL; CELL CYCLE; DISEASE COURSE; DNA METHYLATION; GENETICS; METABOLISM; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

CELL CYCLE; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION;

EID: 59649104770     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.048     Document Type: Review

References (84)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860-73.
2. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2:175-87.
3. Malpas JS, Bergsagel DE, Kyle R, et al. Myeloma: Biology and Management. 3rd ed. Oxford: Elsevier, 2004.
4. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64:1546-58.
5. Magrangeas F, Lodé L, Wuilleme S, et al. Genetic heterogeneity in multiple myeloma. Leukemia 2005; 19:191-4.
6. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23:6333-8.
7. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-54.
8. Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol 2002; 20:167-76.
9. Bird A. The essentials of DNA methylation. Cell 1992; 70:5-8.
10. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24:132-8.
11. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-9.
12. Weinberg RA. Tumor suppressor genes. Science 1991; 254:1138-46.
13. Knudson AG. Karnofsky Memorial Lecture. Hereditary cancer: theme and variations. J Clin Oncol 1997; 15:3280-7.
14. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998; 12:845-59.
15. Siegfried Z, Eden S, Mendelsohn M, et al. DNA methylation represses transcription in vivo. Nat Gene 1999; 22:203-6.
16. Merlo A, Herman JG, Mao L, et al. 5'CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995; 1:686-92.
17. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci 1992; 89:1827-31.
18. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U SA 1996; 93:9821-6.
19. Chim CS, Pang R, Fung TK, et al. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007; 21:2527-36.
20. Chim CS, Liang R, Fung TK, et al. Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma. Leukemia 2005; 19:2352-5.
21. Chim CS, Liang R, Fung TK, et al. Epigenetic dysregulation of the death-associated protein kinase / p14 / HDM2 / p53 /Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol 2007; 60:664-9.
22. Chim CS, Chan WW, Pang A, et al. Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia: an independent poor prognostic factor. Leukemia 2006; 20:907-9.
23. Chim CS, Fung TK, Cheung WC, et al. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the JAK/STAT pathway. Blood 2004; 103:4630-5.
24. Chim CS, Liang R, Leung MH, et al. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol 2007; 60:104-6.
25. Chim CS, Fung TK, Liang R. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia 2003; 17:2533-5.
26. Heinrich PC, Behrmann I, Muller-Newen G, et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334:297-314.
27. O'Shea JJ, Gadina M, Schreiber RD. Cell 2002; 109(suppl):S121-31.
28. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002; 2:410-6.
29. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10:105-15.
30. Myers MP, Andersen JN, Cheng A, et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem 2001; 276:47771.
31. Wu C, Sun M, Liu L, et al. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003; 306:1-12.
32. Galm O, Yoshikawa H, Esteller M, et al. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003; 101:2784-8.
33. Galm O, Wilop S, Reichelt J, et al. DNA methylation changes in multiple myeloma. Leukemia 2004; 18:1687-92.
34. Johan MF, Bowen DT, Frew ME, et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2005; 129:60-5.
35. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347:1593-603.
36. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Cancer Rev 2001; 1:222-31.
37. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86:841-54.
38. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60:3689-95.
39. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999; 18:5311-7.
40. Jeffrey PD, Tong L, Pavletich NP. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev 2000; 14:3115-25.
41. Sherr CJ, Roberts JM. CDK inhibitors : positive and negative regulators of G1-phase progression. Genes & Dev 1999; 13:1501-12.
42. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001; 58:1907-22.
43. Mateos MV, Garcéa Sanz R, López-Pérez R, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002; 118:1034-40.
44. Guillerm G, Gyan E, Wolowiec D, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001; 98:244-6.
45. Krémer A, Schultheis B, Bergmann J, et al. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia 2002; 16:1844-51.
46. Raveh T, Droguett G, Horwitz MS, et al. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 2001; 3:1-7.
47. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2:731-7.
48. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432:307-15.
49. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-6.
50. Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 2003; 21:277-84.
51. Staal FJ, Clevers HC. WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol 2005; 5:21-30.
52. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003; 116:2627-34.
53. Hsieh JC, Kodjabachian L, Rebbert ML, et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 1999; 398:431-6.
54. Melkonyan HS, Chang WC, Shapiro JP, et al. SARPs: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci U S A 1997; 94:13636-41.
55. Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001; 411:321-5.
56. Chim CS, Kwong YL, Fung TK, et al. Methylation profiling in multiple myeloma. Leuk Res 2004; 28:379-85.
57. Mateos MV, Garcia-Sanz R, López-Pérez R, et al. p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J 2001; 2:146-9.
58. Heller G, Schmidt WM, Ziegler B, et al. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 2008; 68:44-54.
59. Chim CS, Liang R, Leung MH, et al. Aberrant gene promoter methylation marking disease progression in multiple myeloma. Leukemia 2006; 20:1190-2.
60. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004; 4:118-32.
61. Cheng SH, Ng MH, Lau KM, et al. 4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4. Blood 2007; 109:2089-99.
62. Turner JG, Gump JL, Zhang C, et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 2006; 108:3881-9.
63. Pompeia C, Hodge DR, Plass C, et al. Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res 2004; 64:3465-73.
64. Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104:607-18.
65. Gonzalez-Paz N, Chng WJ, McClure RF, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 2007; 109:1228-32.
66. Guillerm G, Depil S, Wolowiec D, Quesnel B. Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica 2003; 88:476-8.
67. Takada S, Morita K, Hayashi K, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol 2005; 75:505-10.
68. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412-20.
69. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007; 21:529-34.
70. Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135:158-64.
71. Moreau P, Hullin C, Garban F, et al. Intergroupe Francophone du Myélome group. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006; 107:397-403.
72. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107:3474-80.
73. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21:151-7.
74. Chim CS, Wong SY, Kwong YL. Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance. Br J Haematol 2003; 122:571-8.
75. Chim CS, Lau JS, Wong KF, et al. CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia. Leukemia 2006; 20:149-51.
76. Chim CS, Liang R, Tam CY, et al. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol 2001; 19:2033-40.
77. Chim CS, Kwong YL. Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia. Leuk Lymphoma 2006; 47:815-25.
78. Teofili L, Martini M, Luongo M, et al. Hypermethylation of CpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia repress p15INK4b expression and correlates with poor prognosis. Leukemia 2003; 17:919-24.
79. Blackwood EM, Kadonaga JT. Going the distance: a current view of enhancer action. Science 1998; 281:60-3.
80. Mares J, Kréz V, Weinhéusel A, et al. Methylation changes in promoter and enhancer regions of the WT1 gene in Wilms' tumours. Cancer Lett 2001; 166:165-71.
81. Tatetsu H, Ueno S, Hata H, et al. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res 2007; 67:5328-36.
82. Fahrner JA, Baylin SB. Heterochromatin: stable and unstable invasions at home and abroad. Genes Dev 2003; 17:1805-12.
83. Schmelz K, Wagner M, Dorken B, et al. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005; 114:683-95.
84. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-31.